Articles On Pharmaust (ASX:PAA)

  The ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as the giant released its Q3 report Nimy Resources up 50pc after reporting promising intercepts   The ASX added 0.5% on Thursday as the unemp...

Dr Herbert Brinkman joins PharmAust as head of manufacturing, bringing over 30 years of pharmaceutical product development experience Manufacturing process development agreements signed with Syngene International and Catalent Pharma Soluti...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has strengthened its management team with the appointment of Dr Herbert Brinkman as head of manufacturing. Dr Brinkman has more than 30 years of product development and manufacturing...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has received approval from the human research ethics committee (HREC) at Sydney’s Macquarie University to start an open-label extension study of lead drug monepantel (MPL) on patient...

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac...

Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials  Small Caps led by rare earths developer Arafura   Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T...

Phase 1 MEND study outcomes for MND/ALS treatment now with FDA for review in support of PharmAust’s Orphan Drug Designation request Clinical data shows monepantel (MPL) has the potential to delay the progression of MND/ALS by ~58% PAA on t...

Biotechnology company PharmAust (ASX: PAA) has filed supplementary positive data from a Phase 1 MEND trial of lead drug monepantel with the US Food and Drug Administration’s (FDA) Office of Orphan Products Development. The data was packaged...

The ASX is set to rise again today with futures up 0.28% near 8.30am AEDT. US markets had another subdued night overnight – is the YTD rally losing steam for good, or is this but a temporary lull as traders digest recent CPI? The Dow...

  Local markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary stocks offset losses in materials and Energy  Small Caps led by LBT Innovations   It’s hard to stay afloat when BHP sinks to a near nine-m...

Is it fanciful imagining how rich one could be if only they had invested in a particular ASX stock? I say no, because it keeps you motivated to keep researching and investing. It also reminds you that diversification can not only reduce ri...

ASX health sector rises in line with broader markets in the past five days  AdAlta reports positive Phase 1 extension trial results of AD-214 into IPF Mach7 signs $3.1 million, three-year renewal contract with Penn State Health Morgans h...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

S&P/ASX 200 rose 0.8% in February with Large Cap S&P/ASX 50 underperforming Midcap and Small Ordinaries Tech sector was the big winner up 19% in February as energy and materials sector slumped  Nyrada soars after preclinical study...

PharmAust (ASX:PAA) has announced that it has met its primary safety and tolerability endpoints with monepantel in the Phase 1 MEND study.

Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary ef...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

MPL found to be safe and well tolerated by MND/ALS patients treated under PAA’s Phase 1 trial Drug also found to have reduced disease progression by about 58% This could translate to significant improvements in life expectancy for MND/ALS...

A little-known small-cap stock has rocketed on Wednesday morning after coming out of a two-day trading halt. PharmAust Limited (ASX: PAA) had requested a halt to trading of its shares before the market opened on Monday. On Tuesday evening...

A Phase 1 trial into the effects of lead candidate monepantel (MPL) on patients with motor neurone disease MND / amyotrophic lateral sclerosis (ALS) has delivered top-line results for clinical-stage biotech PharmAust (ASX: PAA). The multi-c...

  Local markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for Energy Small Caps led by Enova Mining   Australian sharemarkets lacked all the vim, vigour and vinegar one associates with victory on Mond...

Momentum investing has been shown to be a successful strategy over the long term. The strategy essentially involves “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”....

  Local markets end flat like an old can of coke on the coffee table Sectors are mixed up. I’m mixed up after all that Small Caps led by Way2VAT again, as well as some cracking local medtechs   It is 4pm on Thursday February 22, and the S...

PharmAust engages globally renowned experts in MND/ALS to form a scientific advisory board (SAB) The SAB will provide expert advice for the development of monepantel to treat MND/ALS The SAB will also support the planning stages for Pharm...

Perth-based clinical-stage biotechnology company PharmAust (ASX: PAA) has pulled together a team of leading scientists to support the investigation of its lead treatment candidate monepantel (MPL). PharmAust is focused on repurposing MPL fo...

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

The ASX200 closed the day up about .7 of a per cent. Most sectors finished in the green, led by materials, up 1.5 per cent. BHP Group is considering putting on hold its WA Nickel operations – due to a major drop in nickel prices. In r...

ASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to a softening US dollar and general commodity weirdness Small caps led by NKOTB, Australian Wealth Advisors Group on a solid debut   Materi...

PharmAust (ASX: PAA) has achieved another significant milestone along the path to gaining approval for the use of monepantel (MPL) in the treatment of motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). The company has received p...

ASX200 ends 0.75pc lower after a long slog back from -1.5pc this morning. Industrial Sector only gainer, thanks to a banger from Downer Edi Small caps led by Blue Star Helium, Rox Resources.   Local share markets trimmed early losses b...

PharmAust announces first patient dosed in 12-month OLE study for patients with MND/ALS All 12 patients from Phase 1 MEND study expected to be enrolled after meeting minimum requirement Analysis shows a 100% survival rate among the 12 Phas...

Biotechnology company PharmAust (ASX: PAA) has dosed the first patient in an open-label extension (OLE) study follow-up to a program which has obtained promising initial results. The OLE study will investigate the long-term safety, tolerabi...

Perth-headquartered clinical-stage biotechnology company, PharmAust (ASX: PAA), has hit another milestone in the assessment of its potential motor neurone disease (MND) treatment monepantel (MPL). The company reports that all patients have...

Drug developer, Pharmaust (ASX:PAA) announces all 12 patients are finished with its phase one MEND study using monepantel (MPL)for Motor Neuron Disease (MND) Each patient received increasing dosages in a staggered approach with the highe...

PharmAust says progression of its programs show it is a strong contender to compete in rare diseases market Deals done in rare disease market increasing as big pharma realises potential of an orphan drug designation PharmAust progressing s...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Biotechnology company PharmAust (ASX: PAA) has progressed its monepantel (MPL) clinical programs for motor neurone disease and canine oncology during the period to end September. The company’s Phase 1 MEND motor neurone disease study was co...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

PharmAust (ASX:PAA) has announced that all patients in Cohort 4 have completed dosing in its Phase 1 MEND study of monepantel (MPL) in patients with motor neurone disease (MND/ALS). The company...

The ASX200 has slipped more than .3 of a per cent in early trade. And that’s a performance that’s slightly better than futures had suggested. Inflation data in this morning shows China’s economy remained stagnant in September with no cha...

PharmAust (ASX:PAA) wraps up cohort four of its phase one MEND study using MPL at 10 mg/kg to treat MND The study is supported by Australia’s largest independent not-for-profit organisation for MND research, FightMND PAA is using the...

Perth-headquartered clinical-stage biotechnology company PharmAust (ASX: PAA) has achieved a significant milestone with the final dosing of patients participating in the assessment of a treatment for the fatal motor neurone disease (MND/ALS...

PAA has finished does all patients in cohort 4 of its phase 1 study in MND/ALS Data from phase 1 expected in Q1 CY24 before a phase 2 trial commences Phase 1 data will support US orphan drug designation application MND/ALS addressable mark...

PharmAust (ASX:PAA) has announced positive top-line data from its Phase 2 veterinary clinical study of monepantel for the treatment of canine B-Cell lymphoma.

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader...

Determination of a clinically safe and efficacious dosing regimen of monepantel (MPL) for the treatment of dogs with B-Cell Lymphoma Treatment with MPL was safe, well-tolerated and there were no treatment-related deaths or severe adverse r...

PharmAust (ASX: PAA) has confirmed positive top-line data from a Phase 2 veterinary clinical study of its lead candidate monepantel (MPL) for the treatment of canine B-cell lymphoma. The study aimed to determine a clinically-safe and effica...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...